Big Buttons

• CALL TO ACTION: Tell FDA to deny drugmakers’ request

  Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →

• APC to FDA: Just say no to Lilly

  This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →

• California BOP sends proposed compounding regs to comment period

  The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →

• Checking in on the post-Chevron fallout

  What’s happened in the world of federal regulation since the end of Chevron? read more →

• Hi, Noom!

  Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

More News

We’ve been bugging the California Board of Pharmacy (politely!) for a while, trying to get a statement on its position and enforcement posture regarding the compounding of FDA-approved drugs that are currently in shortage. There has been some confusion — mixed messages, you might say — coming out of the Golden State regarding how the BoP views GLP-1 compounding, and we wanted some official clarification.

Good things, apparently, come to those who wait. In this case, it’s a response from the board in a letter last week saying that, “In general, the Board does try to align with FDA when possible,” and also reminding us that compounding pharmacies “must comply with a myriad of state and federal laws.” The bottom line, though — and our take on the letter (you can read it here) — is that the CA BoP’s position on GLP-1 compounding is consistent with that of FDA. 

APC will soon be releasing a best practices document related to shortage drug compounding, including GLP-1s, that tracks to law, FDA guidance, and USP standards … and also recommends certain testing and other measures that go beyond those standards. Stay tuned.